313 related articles for article (PubMed ID: 33970401)
1. Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study.
Goldman A; Bomze D; Dankner R; Fourey D; Boursi B; Arad M; Maor E
Target Oncol; 2021 Jul; 16(4):471-483. PubMed ID: 33970401
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.
Goldman A; Bomze D; Dankner R; Hod H; Meirson T; Boursi B; Maor E
Br J Clin Pharmacol; 2021 Mar; 87(3):1432-1442. PubMed ID: 32964535
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.
Salem JE; Manouchehri A; Moey M; Lebrun-Vignes B; Bastarache L; Pariente A; Gobert A; Spano JP; Balko JM; Bonaca MP; Roden DM; Johnson DB; Moslehi JJ
Lancet Oncol; 2018 Dec; 19(12):1579-1589. PubMed ID: 30442497
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Toxicities Associated With Ibrutinib.
Salem JE; Manouchehri A; Bretagne M; Lebrun-Vignes B; Groarke JD; Johnson DB; Yang T; Reddy NM; Funck-Brentano C; Brown JR; Roden DM; Moslehi JJ
J Am Coll Cardiol; 2019 Oct; 74(13):1667-1678. PubMed ID: 31558250
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021.
Wang Y; Cui C; Ren X; Dong X; Cui W
Front Cardiovasc Med; 2022; 9():988013. PubMed ID: 36312283
[TBL] [Abstract][Full Text] [Related]
6. Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy.
Goldman A; Maor E; Bomze D; Liu JE; Herrmann J; Fein J; Steingart RM; Mahmood SS; Schaffer WL; Perales MA; Shouval R
J Am Coll Cardiol; 2021 Nov; 78(18):1800-1813. PubMed ID: 34711339
[TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials.
Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular toxicities following the use of tyrosine kinase inhibitors in hepatocellular cancer patients: a retrospective, pharmacovigilance study.
Lai X; Wan Q; Jiao SF; Sun XC; Hu JF; Peng HW
Expert Opin Drug Saf; 2024 Mar; 23(3):287-296. PubMed ID: 37608525
[TBL] [Abstract][Full Text] [Related]
9. Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System.
Raschi E; Fusaroli M; Giunchi V; Repaci A; Pelusi C; Mollica V; Massari F; Ardizzoni A; Poluzzi E; Pagotto U; Di Dalmazi G
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230533
[No Abstract] [Full Text] [Related]
10. Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System.
Barbieri MA; Russo G; Sorbara EE; Cicala G; Franchina T; Santarpia M; Speranza D; Spina E; Silvestris N
Front Oncol; 2023; 13():1268672. PubMed ID: 38023143
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitors targeting vascular endothelial growth factor and the risk of aortic dissection-A pharmacovigilance analysis.
Dörks M; Jobski K; Herget-Rosenthal S; Hoffmann F; Douros A
Pharmacol Res Perspect; 2021 Feb; 9(1):e00707. PubMed ID: 33421342
[TBL] [Abstract][Full Text] [Related]
12. Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study.
Goldman A; Raschi E; Cukierman-Yaffe T; Dankner R; Shouval R; Shechter M; Ben-Zvi I; Gerstein HC; Maor E
Eur J Prev Cardiol; 2022 Jul; 29(9):1334-1342. PubMed ID: 34897409
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities.
Allenbach Y; Anquetil C; Manouchehri A; Benveniste O; Lambotte O; Lebrun-Vignes B; Spano JP; Ederhy S; Klatzmann D; Rosenzwajg M; Fautrel B; Cadranel J; Johnson DB; Moslehi JJ; Salem JE
Autoimmun Rev; 2020 Aug; 19(8):102586. PubMed ID: 32535094
[TBL] [Abstract][Full Text] [Related]
14. A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database.
Sun R; Ning Z; Qin H; Zhang W; Teng Y; Jin C; Liu J; Wang A
Sci Rep; 2024 Apr; 14(1):9552. PubMed ID: 38664423
[TBL] [Abstract][Full Text] [Related]
15. Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database.
Hu F; Zhai Y; Yuan L; Liang J; Xu J; Guo X; Zhou X; Lin Z; Sun J; Ye X; He J
Cancer Med; 2021 Dec; 10(24):8754-8762. PubMed ID: 34845857
[TBL] [Abstract][Full Text] [Related]
16. Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database.
Zhao H; Li JM; Li ZR; Zhang Q; Zhong MK; Yan MM; Qiu XY
Front Pharmacol; 2023; 14():1182113. PubMed ID: 37502210
[No Abstract] [Full Text] [Related]
17. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
18. Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: A systemic review and network meta-analysis.
Chen YC; Chen JH; Hsieh FI
J Chin Med Assoc; 2024 Jan; 87(1):48-57. PubMed ID: 37991373
[TBL] [Abstract][Full Text] [Related]
19. Safety profile of vascular endothelial growth factor receptor tyrosine-kinase inhibitors in pediatrics: a pharmacovigilance disproportionality analysis.
Xue Y; Feng S; Li G; Zhang C
Front Pharmacol; 2023; 14():1160117. PubMed ID: 37377925
[No Abstract] [Full Text] [Related]
20. Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database.
Wei L; Tian Y; Chen X; Guo X; Chen C; Zheng Y; Xu J; Ye X
Int J Clin Pharm; 2023 Jun; 45(3):622-629. PubMed ID: 36848023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
